EGFR and head and neck squamous cell carcinoma: To assess the effects of EGFR inhibition on the genes in the Hypoxia-Immune signature, we evaluated pre- and post-cetuximab gene expression from a window-of-opportunity study in patients with HNSCC treated with three doses of cetuximab prior to surgery, as described previously (34).